RelB Activation Profiling for Cancer Fatty Acid Oxidation Risk
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments face challenges due to metabolic reprogramming in cancer cells, particularly towards fatty acid oxidation, leading to resistance and aggressive behavior, necessitating tools for detection and therapeutic interventions.
Innovation Solution
The method involves detecting RelB activation and its associated gene expression signature in cancer cells to classify metabolic reprogramming risk, using inhibitors to target lipid synthesis or fatty acid oxidation, and employing specific inhibitors to impede this reprogramming.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anti-tumor therapies are used, then initial treatment effect is achieved, but metabolic reprogramming leads to resistance and treatment failure
Solution Approach 1:
The patent performs preliminary detection of RelB activation status and metabolic reprogramming risk before initiating treatment. By identifying the gene expression signature and RelB activation early, the method enables proactive selection of patients who would benefit from lipid metabolism inhibitors, preventing treatment failure before it occurs rather than reacting to resistance after it develops.
Solution Approach 2:
The patent dynamically adapts treatment strategy based on detected metabolic state. Patients with RelB activation and high metabolic reprogramming risk receive lipid metabolism inhibitors in combination with conventional therapy, while those without this signature receive standard treatment alone. This dynamic, personalized approach allows treatment to adapt to the patient's specific metabolic profile.
2Reliability
If lipid metabolism inhibitors are used, then therapeutic effect is improved in RelB-activated cancers, but treatment complexity increases
Solution Approach 1:
The patent applies local quality by tailoring treatment to specific patient subgroups based on their molecular characteristics. Only patients with RelB activation and the specific gene expression signature receive the complex combination therapy with lipid metabolism inhibitors, while other patients receive simpler conventional monotherapy. This localized application of complex treatment to the appropriate subset of patients optimizes efficacy without unnecessarily complicating treatment for all patients.
3Adaptability or versatility
If metabolic reprogramming detection is performed, then treatment personalization is enabled, but diagnostic complexity increases
Solution Approach 1:
The patent employs a universal gene expression signature comprising 136 genes that can be measured using standard RNA sequencing or microarray technology already widely available in clinical settings. This multi-functional approach allows the same diagnostic platform to detect metabolic reprogramming risk across different cancer types and contexts, enabling treatment personalization without requiring specialized or complex diagnostic equipment.
Data Source
AI summary
The invention relates to an in vitro method for classifying a subject afflicted with a cancer as suffering from a cancer with (at risk of) a metabolic reprograming towards fatty acids oxidation including a step of assaying the activation of RelB in a tumor sample form said cancer. The inventor indeed identified the pivotal role of RelB in energy metabolism and more particularly mitochondrial respiration and fatty acid oxidation. Accordingly, the invention also relates to inhibitors of RelB activity or expression, as well as of lipid metabolism for use in the treatment of cancers showing an activated RelB.